Previous studies [2, 16] had suggested that acarbose was useful in reducing the risk of MACE in patients with IGT; its cardiovascular protective effect might be due to the reduction of postprandial hyperglycemia and glucose variability, increased insulin sensitivity, induction of moderate weight loss, restoration of endothelial function, and so forth [17]. This evidence concerns the gene INS and Hyperglycemia.